Institutional members access full text with Ovid®

Share this article on:

Use of β-Agonists in Inhalation Injury

Palmieri, Tina L. MD, FACS, FCCM

doi: 10.1097/BCR.0b013e3181923bc3
Inhalation Therapies

Damage to the pulmonary parenchyma from smoke represents a second cause of inhalation injury. To date, the treatment of lung injury due to smoke has been largely supportive in nature. Patients are intubated, placed on mechanical ventilation, and maintained on support until pulmonary status improves, permanent airway access obtained, or the patient dies. Given that the insult associated with inhalation injury causes direct pulmonary damage and that the lungs have the ability of absorb drugs, the use of inhaled therapies for inhalation injury is appealing. The goal of this chapter is to describe the potential role of inhalation therapies in the treatment of smoke inhalation injury.

From the Department of Burn Surgery, Shriners Hospital for Children Northern California; and Department of Surgery, University of California Davis, Sacramento.

This study was supported by Shriners Hospital for Children Grant #8431.

Address correspondence to Tina L. Palmieri, MD, FACS, FCCM, 2425 Stockton Blvd, Suite 718, Sacramento, California 95817.

© 2009 The American Burn Association